Cargando…

Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan

BACKGROUND: Medicaid coverage for smoking cessation medications has expanded; however, little research has been conducted to evaluate patient-level changes in medication use over time and its associated economic impact on health plans. OBJECTIVE: The aim of this study was to characterize trends in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Corelli, Robin L., Tu, Thanh G., Lee, Kyoung J., Dinh, Drake, Gericke, Kristin R., Hudmon, Karen Suchanek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611121/
https://www.ncbi.nlm.nih.gov/pubmed/34109569
http://dx.doi.org/10.1007/s41669-021-00274-7
_version_ 1784603236975509504
author Corelli, Robin L.
Tu, Thanh G.
Lee, Kyoung J.
Dinh, Drake
Gericke, Kristin R.
Hudmon, Karen Suchanek
author_facet Corelli, Robin L.
Tu, Thanh G.
Lee, Kyoung J.
Dinh, Drake
Gericke, Kristin R.
Hudmon, Karen Suchanek
author_sort Corelli, Robin L.
collection PubMed
description BACKGROUND: Medicaid coverage for smoking cessation medications has expanded; however, little research has been conducted to evaluate patient-level changes in medication use over time and its associated economic impact on health plans. OBJECTIVE: The aim of this study was to characterize trends in smoking cessation medication utilization between 2006 and 2017 within a Medicaid population and estimate per-member per-month (PMPM) costs to the health plan. METHODS: This study was a retrospective longitudinal analysis conducted among adult members of a Medicaid managed care plan in California. Pharmacy claims data from January 1, 2006 to December 31, 2017 were analyzed to estimate utilization and cost of smoking cessation medications. Additionally, data from 3164 members who filled prescription(s) for cessation medication(s) in 2017 were evaluated to quantify quit attempts and use of combination therapy. For members who had been prescribed bupropion SR, varenicline, or the nicotine patch, the extent to which the durations of therapy were consistent with the manufacturers’ recommended minimum duration of therapy were also assessed. RESULTS: The average PMPM expenditures for smoking cessation medications were approximately US$0.15 in 2017, compared with US$0.01–US$0.03 between 2006 and 2013. In 2017, a total of 3164 members initiated an estimated 3850 quit attempts, most commonly using the nicotine patch (57.5%) or varenicline (32.8%). Combination therapy accounted for 2.9% of quit attempts. The median therapy duration for the nicotine patch, varenicline, and bupropion SR was 28, 30, and 33 days, respectively, and for each of these medications, fewer than half of members filled prescriptions for the minimum recommended duration of therapy. CONCLUSIONS: Pharmacy claims data suggest that despite comprehensive coverage, most beneficiaries are underutilizing smoking cessation agents and are not completing the recommended treatment durations.
format Online
Article
Text
id pubmed-8611121
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-86111212021-12-10 Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan Corelli, Robin L. Tu, Thanh G. Lee, Kyoung J. Dinh, Drake Gericke, Kristin R. Hudmon, Karen Suchanek Pharmacoecon Open Original Research Article BACKGROUND: Medicaid coverage for smoking cessation medications has expanded; however, little research has been conducted to evaluate patient-level changes in medication use over time and its associated economic impact on health plans. OBJECTIVE: The aim of this study was to characterize trends in smoking cessation medication utilization between 2006 and 2017 within a Medicaid population and estimate per-member per-month (PMPM) costs to the health plan. METHODS: This study was a retrospective longitudinal analysis conducted among adult members of a Medicaid managed care plan in California. Pharmacy claims data from January 1, 2006 to December 31, 2017 were analyzed to estimate utilization and cost of smoking cessation medications. Additionally, data from 3164 members who filled prescription(s) for cessation medication(s) in 2017 were evaluated to quantify quit attempts and use of combination therapy. For members who had been prescribed bupropion SR, varenicline, or the nicotine patch, the extent to which the durations of therapy were consistent with the manufacturers’ recommended minimum duration of therapy were also assessed. RESULTS: The average PMPM expenditures for smoking cessation medications were approximately US$0.15 in 2017, compared with US$0.01–US$0.03 between 2006 and 2013. In 2017, a total of 3164 members initiated an estimated 3850 quit attempts, most commonly using the nicotine patch (57.5%) or varenicline (32.8%). Combination therapy accounted for 2.9% of quit attempts. The median therapy duration for the nicotine patch, varenicline, and bupropion SR was 28, 30, and 33 days, respectively, and for each of these medications, fewer than half of members filled prescriptions for the minimum recommended duration of therapy. CONCLUSIONS: Pharmacy claims data suggest that despite comprehensive coverage, most beneficiaries are underutilizing smoking cessation agents and are not completing the recommended treatment durations. Springer International Publishing 2021-06-09 /pmc/articles/PMC8611121/ /pubmed/34109569 http://dx.doi.org/10.1007/s41669-021-00274-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Corelli, Robin L.
Tu, Thanh G.
Lee, Kyoung J.
Dinh, Drake
Gericke, Kristin R.
Hudmon, Karen Suchanek
Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
title Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
title_full Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
title_fullStr Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
title_full_unstemmed Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
title_short Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
title_sort smoking cessation pharmacotherapy utilization and costs to a medicaid managed care plan
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611121/
https://www.ncbi.nlm.nih.gov/pubmed/34109569
http://dx.doi.org/10.1007/s41669-021-00274-7
work_keys_str_mv AT corellirobinl smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan
AT tuthanhg smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan
AT leekyoungj smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan
AT dinhdrake smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan
AT gerickekristinr smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan
AT hudmonkarensuchanek smokingcessationpharmacotherapyutilizationandcoststoamedicaidmanagedcareplan